Prestige Consumer Healthcare (PBH) Expected to Announce Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) will likely be releasing its Q3 2025 earnings data before the market opens on Thursday, February 6th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.18 per share and revenue of $287.07 million for the quarter. Prestige Consumer Healthcare has set its FY 2025 guidance at 4.500-4.500 EPS.Parties that are interested in registering for the company's conference call can do so using this link.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Down 0.4 %

Shares of NYSE:PBH traded down $0.39 during trading on Friday, reaching $86.96. 523,063 shares of the company traded hands, compared to its average volume of 288,972. The firm has a fifty day simple moving average of $79.23 and a 200 day simple moving average of $75.48. The company has a quick ratio of 2.10, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare has a 1-year low of $60.00 and a 1-year high of $88.36. The firm has a market cap of $4.30 billion, a P/E ratio of 20.37, a price-to-earnings-growth ratio of 2.43 and a beta of 0.50.

Analyst Ratings Changes

PBH has been the subject of a number of research reports. DA Davidson lifted their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Canaccord Genuity Group lifted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $92.50.

Insider Transactions at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares of the company's stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William P'pool sold 8,987 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares of the company's stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,810 shares of company stock worth $3,187,300. Insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.